[Federal Register: December 1, 2009 (Volume 229, Number 74)] [Notices] [Page 62793-62795] From the Federal Register Online via GPO Access [wais.access.gpo.gov] [DOCID:fr01de09-77] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA-2007-D-0369] (formerly Docket No. 2007D-0168) Draft and Revised Draft Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability AGENCY: Food and Drug Administration, HHS. ACTION: Notice. ----------------------------------------------------------------------- SUMMARY: The Food and Drug Administration (FDA) is announcing the availability of additional draft and revised draft product-specific bioequivalence (BE) recommendations. The recommendations provide product-specific guidance on the design of BE studies to support abbreviated new drug applications (ANDAs). In the Federal Register of May 31, 2007, FDA announced the availability of a draft guidance for industry entitled ``Bioequivalence Recommendations for Specific Products,'' explaining the process that would be used to make product- specific BE recommendations available to the public on FDA's Web site. The BE recommendations identified in this notice were developed using the process described in that guidance. DATES: Submit written or electronic comments on the draft and revised draft product-specific BE recommendations listed in this notice by February 1, 2010. ADDRESSES: Submit written requests for single copies of the individual BE guidances to the Division of Drug Information, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, rm. 2201, Silver Spring, MD 20993-0002. Send one self-addressed adhesive label to assist that office in processing your requests. Submit written comments on the draft product-specific BE recommendations to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Submit electronic comments to http://www.regulations.gov. See the SUPPLEMENTARY INFORMATION section for electronic access to the draft guidance recommendations. FOR FURTHER INFORMATION CONTACT: Doan T. Nguyen, Center for Drug Evaluation and Research (HFD-600), Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855, 240-276-9314. SUPPLEMENTARY INFORMATION: I. Background In the Federal Register of May 31, 2007 (72 FR 30388), FDA announced the availability of a draft guidance for industry entitled ``Bioequivalence Recommendations for Specific Products,'' that explained the process that would be used to make product-specific BE recommendations available to the public on FDA's Web site at http:// www.fda.gov/CDER/GUIDANCE/bioequivalence/default.htm. As described in that draft guidance, FDA adopted this process as a means to develop and disseminate product-specific BE recommendations and provide a meaningful opportunity for the public to consider and comment on those recommendations. Under that process, draft recommendations are posted on FDA's Web site and announced periodically in the Federal Register. The public is encouraged to submit comments on those recommendations within 60 days of their announcement in the Federal Register. FDA considers any comments received and either publishes final recommendations, or publishes revised draft recommendations for comment. Recommendations were last announced in the Federal Register of June 8, 2009 (74 FR 27146). This notice announces draft product- specific recommendations, either new or revised, that have been posted on FDA's Web site in the period from November 1, 2008, through December 1, 2009. II. Drug Products for Which New Draft Product-Specific BE Recommendations Are Available FDA is announcing draft BE product-specific recommendations for drug products containing the following active ingredients: A Adapalene (multiple reference listed drugs (RLDs)) Adapalene; Benzoyl Peroxide Alendronate Sodium; Cholecalciferol Aliskiren Hemifumarate Aliskiren Hemifumarate; Hydrochlorothiazide Allopurinol Ambrisentan Amlodipine Besylate; Atorvastatin Calcium Atenolol B Bromfenac Sodium Bromocriptine Budesonide C Calcium Acetate Cephalexin Chlorpheniramine Polistirex; Hydrocodone Polistirex Ciprofloxacin Clonidine Clotrimazole (multiple RLDs) D Desmopressin Acetate Desogestrel; Ethinyl Estradiol (multiple RLDs) Desvenlafaxine Succinate Dextroamphetamine Sulfate Dextromethorphan Hydrobromide; Guaifenesin Diclofenac Sodium (multiple RLDs) Doxycycline Hyclate Drospirenone; Ethinyl Estradiol E Eletriptan Hydrobromide [[Page 62794]] Estradiol (multiple RLDs) Ethinyl Estradiol; Levonorgestrel (multiple RLDs) Ethinyl Estradiol; Norelgestromin Ethinyl Estradiol; Norethindrone Acetate (multiple RLDs) Ethinyl Estradiol; Norgestrel (multiple RLDs) F Famotidine Felodipine Fenoprofen Calcium Fentanyl Fexofenadine HCl Fexofenadine; Pseudoephedrine (multiple RLDs) Fludrocortisone Acetate G Glimepiride; Pioglitazone HCl Glycopyrrolate Guaifenesin; Pseudoephedrine HCl H Haloperidol Hydrocodone Bitartrate; Acetaminophen Hydroxyzine Pamoate (multiple RLDs) I Imatinib Mesylate L Lansoprazole Levetiracetam Linezolid Loratadine M Meprobamate Metformin HCl (multiple RLDs) Metformin HCl; Repaglinide Methotrexate Sodium (multiple RLDs) Metoclopramide HCl Miconazole Nitrate (multiple RLDs) Mycophenolic Acid N Nadolol Naltrexone Niacin Nifedipine Nilutamide Nisoldipine Nitazoxanide Nitrofurantoin Nitrofurantoin Macrocrystalline Norethindrone Norethindrone Acetate O Oxybutynin Chloride P Phendimetrazine Tartrate (multiple RLDs) Phentermine HCl (multiple RLDs) Phytonadione Pramipexole Dihydrochloride Prednisolone Pregabalin Propafenone HCl Pyridostigmine Bromide R Raltegravir Potassium Ramelteon Raniditine (multiple RLDs) Rasagiline Mesylate Rivastigmine Tartrate S Scopolamine Selegiline Sodium Phenylbutyrate (multiple RLDs) Sorafenib Tosylate T Tamoxifen Citrate Telbivudine Temazepam Terbinafine HCl Toremifene Citrate Trandolapril; Verapamil HCl Triamcinolone Acetonide (multiple RLDs) V Voriconazole Z Zolpidem III. Drug Products for Which Revised Draft Product-Specific BE Recommendations Are Available FDA is announcing revised draft BE product-specific recommendations for drug products containing the following active ingredients. These recommendations were previously posted on FDA's Web site: A Azacitidine B Busulfan C Carbidopa; Entacapone; Levodopa D Darunavir Ethanolate Desogestrel; Ethinyl Estradiol Doxercalciferol E Ethinyl Estradiol; Norethindrone (multiple RLDs) F Fluoxetine HCl; Olanzapine H Hydrochlorothiazide; Lisinopril I Ibuprofen L Lansoprazole Lovastatin; Niacin M Methylprednisolone Acetate Melphalan N Nabilone O Omeprazole; Sodium Bicarbonate Q Quetiapine Fumarate R Risedronate Sodium S Sevelamer Carbonate Sevelamer HCl Sildenafil Citrate T Temozolomide Topiramate Tacrolimus For a complete history of previously published Federal Register notices, please go to http://www.regulations.gov and enter docket number FDA-2007-D-0369. These guidances are being issued consistent with FDA's good guidance practices regulation (21 CFR 10.115). The guidances represent the agency's current thinking on product-specific design of BE studies to support ANDAs. They do not create or confer any rights for or on any person and do not operate to bind FDA or the public. An alternative approach may be used if such approach satisfies the requirements of the applicable statutes and regulations. IV. Comments Interested persons may submit to the Division of Dockets Management (see ADDRESSES) written or electronic comments on any of the specific BE recommendations posted on FDA's Web site. Submit a single copy of electronic comments or two paper copies of mailed comments, except that individuals may submit one paper copy. Comments are to be identified with the docket number found in brackets in the heading of this document. The guidance, notices, and received comments may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday. V. Electronic Access Persons with access to the Internet may obtain the document at either http://www.fda.gov/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/default.htm or http:/ /www.regulations.gov. [[Page 62795]] Dated: November 20, 2009. David Horowitz, Assistant Commissioner for Policy. [FR Doc. E9-28593 Filed 11-30-09; 8:45 am] BILLING CODE 4160-01-S
Justia Lawyer, Legal Aid & Services Directory: Health Care Lawyers